Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
XNPT
Nothing new in the JP Morgan webcast, except for the first time the CEO said the company was in active negotiations for US and worldwide partnerships for the gabapentin analog and worldwide/regional rights for the baclofen analog.
I find it unlikely that this company will ever have to dilute. They have ~$100 million in the bank right now; using the Astellas deal as a metric, I would imagine US and European rights to the gabapentin analog would go for $75-100 million each plus larger royalties. Keep in mind that Astellas has to take the drugs back through phase I in Japan to comply with Japanese regulatory requirements, whereas the US and European rights come with a phase III program in place.
The CEO also noted that the phase III program in RLS will consist of two 12-week studies (sounded like they were simultaneous) and a 24-week study measuring relapse.
Not sure how much the baclofen analog is worth. For spasticity, not much; for GERD, a lot. Phase II results coming 1H06.
With only 19 million shares out and thin trading, it's been a bit of a wild ride.
J
DND.to
io_io,
I'd love to see a RMF for DND.
Are they getting a US listing?
John
MDCO
Re: bivalirudin
Recently had the opportunity to go through the new PCI guidelines in detail, and couldn't believe that bivalirudin is now recommended as a substitute for GP IIb-IIIa inhibition in low-risk patients.
The recommendation is based on the results of REPLACE-2, which is an incredibly flawed trial--can't believe the guidelines committee fell for it. 1) The criteria for major and minor bleeding were not standard TIMI criteria; when you apply standard TIMI criteria there is no statistically significant difference between the hep/GP IIb-IIIa arm and the bivalirudin arm; 2) >100 patients in the hep/GP IIb-IIIa arm did not receive GP IIb-IIIa inhibitors, and about 25% received substantially less than the recommended duration of therapy. Despite all this--which you would think would put eptifibatide at a substantial disadvantage--point estimates generally favored eptifibatide, although these differences were not significant.
Moreover, coagulation and platelet aggregation are two completely different physiological processes. Inhibiting one without the other is just plain bad practice. No, you may not see a large number of overt events in patients who receive bivalirudin, but the sub-clinical events, as measured by CK-MB elevation, will be frequent. These sub-clinical events have long-term repercussions in terms of mortality.
Can't wait to see the results of ACUITY. I'm sure we can expect an equally manipulative presentation of the data.
WTF? The marketing officer posting on a message board. Serious danger...sorry not wasting any more time on this.
Moderator: Please don't delete this message--if you have a look at my previous posts you will see that I am far from a basher.
Randy,
Sorry--but I find that post extremely frightening.
>WE HAVE THE OFFICIAL REPORT FROM THE INDEPENDENT STATSITICIAN, WHICH I WILL SEND
YOU. WE ARE ALSO PLANNING NOW TO HAVE THE LEAD CLINICAL INVESTIGATOR, DR PAUL
RATNER, MD, AUTHOR A PUBLICATION THAT WILL BE SUBMITTED TO THE MAJOR
PEER-REVIEWED MEDICAL JOURNALS. I WILL SEND YOU A COPY ONCE THAT IS WRITTEN<
This is completely wrong--they can't send an individual investor a copy of the study report or the pre-publication paper.
>NOT SURE WHAT YOU MEAN BY 'EMEA'??<
This is particularly frightening.
Who is this person? Why do they type in all caps?
I'd be afraid, very afraid.
Sorry...I did look into this, but really all I needed to see was this post.
YMI--JP Morgan
Does anyone know if YMI is presenting at JP Morgan? It is listed on their web site, but is not on the agenda.
I'll call YMI, but I'm sure they are tired of being harassed by me.
J
I guess CRME would be the first-best?
Congrats on your foray into the Canadians!
YMI
In case nobody noticed, YMI is within 1% of its all-time high.
Re: torcetrapib
>Below a certain point reduction in LDL has diminishing returns on that hard endpoint.<
Not really.
Part of my point was that the CTT meta-analysis clearly demonstrates a linear relationship between LDL-C reductions and reduction in risk for major coronary events and major vascular events. No lower limit was observed below which further reductions in LDL-C did not reduce risk. The CTT's conclusion is also supported by the results of HPS, which showed that relative risk for CHD is reduced in a linear fashion until LDL-C reaches 40 mg/dL.
So you are partly right. Below 40 mg/dL there is little incremental benefit to be obtained. However, 40 mg/dL is so low that is, in practical terms, nearly impossible to achieve. At least with a "Western" diet and lifestle.
Targets--such as those defined by the NCEP ATP III--are developed based on what is achievable in the real world. Realistically, the results of CTT and HPS suggest we'd all be better off with LDL-C levels of 40 mg/dL. However, current therapies are unlikely to achieve these levels even in individuals with normal pretreatment cholesterol levels, so this target was not used in the guidelines.
>If all Torcetrapib shows conclusively is that it lowers LDL by 20% incremental to what high-dose Lipitor monotherapy can do (McKinnell’s worst-case scenario), McKinnell thinks this is still enough to make Torcetrapib a very big seller.<
A 20% reduction in LDL should result in a significant reduction in morbidity and mortality.
According the Cholesterol Treatment Trialists' recent meta-analysis, each mmol/L reduction in LDL-C (about 39 mg/dL) provides a 12% reduction in all-cause mortality, largely due to a 19% reduction in coronary mortality. Each mmol/L reduction in LDL-C also yields about a 23% reduction in the composite of MI or coronary death, a 24% reduction in the need for revascularization, and a 17% reduction in fatal or non-fatal stroke (all P<.0001).
So let's say you have a patient with baseline LDL-C of 180 mg/dL, which is slightly above the NCEP ATP III cutoff of 160 mg/dL for someone with 0-1 risk factors and without established CHD or CHD risk equivalents. Torcetrapib alone would yield a 36 mg/dL reduction in LDL-C, which--in light of the data above--is nearly enough to achieve a 19% reduction in coronary mortality, an end point that I'd assume would be part of the primary composite end point for a morbidity and mortality trial of this agent. These figures are for a 20% reduction; keep in mind that up to 42% reductions in LDL-C have been demonstrated with torcetrapib.
Moreover, the CTT meta-analysis confirmed that there is no lower LDL-C limit beyond which further reduction in risk are not achieved.
Conclusions? 1) Torcetrapib is likely to show added benefit over and above a statin alone in a hard end point trial. 2) HDL effects are likely to contribute further to these benefits 3) Toreceptapib is likely to add real value, whether used with Lipitor, another statin, or even alone.
Sorry if my post is long winded.
I'll take that bet. However, I think that the once-daily dosing and lack of an oral formulation will kill it in the marketplace unless it really has blow-out results. Also watch the QTc issue. I think it has been resolved positively, but even one case is going to cause a serious problem.
I want to say one more time that I don't have a problem with THRX, the management, or the science. I just got tired of the incessant analyst pumping of a company I felt to be significantly overvalued. To be honest, I also got sick of hearing about it from my colleagues in the industry. And to be even more honest, I was irritated becuase they're not pumping my favorites.
XNPT...oh the pain. Falling hard in very low volume. It's the reason my overall portfolio is down. I like XNPT, but with only 19M shares out, it's been a rollercoaster ride from hell. Of course the positive here is that with their cash in the bank, it is unlikely they will ever have to dilute.
Regarding the DEPO's results, they are good but unsuprising. What I'd like to see there is a study similar to the one XNPT conducted showing incremental benefit with their product. Anyway, I'm far more interested in gabapentin for RLS as it is a less crowded market.
It is unlikely I'll hold XNPT through approval. I'm banking on a one or two big fat partnerships in the first half of the year. I am worried about the baclofen analog--no particular reason except that the results will be out relatively soon and there are few well-conducted studies supporting efficacy in GERD, although these studies are positive.
THRX
I have maintained that THRX is overvalued, in part because telavancin is entering a crowded market without showing any signs of superiority to established treatments and because I view the phase 2a products as vaporware.
So far, one analyst agrees.
******************************************************
Theravance Inc. shares dipped nearly 5 percent Thursday after a Credit Suisse First Boston analyst argued that the stock is overvalued, given the likelihood that one of its key drugs will be delayed and another won't prove superior to competing treatments.
"We believe that the Street does not fully appreciate the risks associated with the company's two lead programs," analyst Mark Augustine wrote in a note to clients.
Augustine lowered his price target for Theravance shares to $18 from $22, and said he now expects the stock to underperform the industry average. Previously, Augustine had predicted that Theravance's performance would be in line with its peers.
The company's stock closed down 92 cents, or 4.3 percent, at $20.51 on the Nasdaq, and earlier dipped as low as $19.20.
Augustine said there are risks of further delays for a product Theravance is developing for asthma and certain lung diseases. The South San Francisco, Calif.-based company has partnered with GlaxoSmithKline on the drug, and Augustine said extra time could mean that a Glaxo-discovered drug will become the lead candidate in the partnership, reversing certain milestone payments.
He further added that an antibiotic the Theravance is developing, telavancin, is likely to just match an existing competitor, vancomycin, in effectiveness. He argued the drug needs to prove superior to vancomycin to become a commercial success.
Augustine also cut his rating on Genentech Inc., Imclone Systems Inc. and Biogen Idec Inc. on Thursday, while upgrading Cytokinetics, which closed up 28 cents, or 4.5 percent, at $6.46 on the Nasdaq, after earlier trading as high as $7.
Speaking of contrarian indicators...
I'm having an awful week. Three straight days down after 10 up days in a row in the final weeks of December. Is it just my portfolio, or is it small-cap bio in general?
Just depressed to see the market go straight up without me.
John
ST-segment elevation
Myocardial infarction is usually classified into non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI). The “ST” refers to a part of an electrocardiogram that can indicate ischemia.
The following is a cut and paste from something I wrote for other purposes (not edited or fact checked, so take it for what it’s worth:
Acute coronary syndromes are characterized by an imbalance between myocardial oxygen supply and demand. Inflammation and/or infection may weaken the structure of the fibrous cap that overlies the atherosclerotic plaque. Rupture or erosion of an atherosclerotic plaque exposes the lipid-rich, thrombogenic contents of the plaque to the blood, resulting in the initiation of a complex cascade of events the culminates in the formation of occlusive or non-occlusive thrombus. The platelet-rich thrombus can release a variety of vasoconstrictors, resulting in vasoconstriction at the site of plaque rupture and exacerbating the oxygen supply/demand imbalance.
Patients with ACS are categorized into those with persistent ST-segment elevation myocardial infarction (STEMI), which generally reflects acute total coronary occlusion, and those without persistent ST-segment elevation (non-ST-segment myocardial infarction; NSTEMI). Patients without ST-segment elevation may be further subcategorized into those with unstable angina or non-ST-segment myocardial infarction.
Patients with myocardial infarction are also categorized based on the presence or absence of myocardial necrosis, which is reflected in changes in QRS pattern (non-Q-wave myocardial infarction and Q-wave myocardial infarction).
Treatment options vary based on ACS categorization. Among patients with UA or NSTEMI, treatment options include anti-ischemic agents (beta-blockers, nitrates, potassium channel activators, and calcium channel blockers), anti-thrombin therapy (heparin, low-molecular-weight heparin, and direct thrombin inhibitors), antiplatelet agents (aspirin, theinopyridines, glycoprotein IIb-IIIa inhibitors), fibrinolytic treatment, coronary revascularization, lipid-lowering therapy, and ACE inhibitors.
Among patients with STEMI, rapid restoration of coronary flow with fibrinolytic treatment and/or primary angioplasty is indicated.
If you have made it this far, can you guess what category of drug I'm introducing?
And I took that back. It's only 2-fold overvalued. I won't restate my argument here, other than to say that, although THRX is a fine company, there are plenty of places to put one's money that offer superior risk/reward. In my opinion, of course.
Re: HGSI
Agree with you 100% on that one. Other hugely overvalued stocks I would touch with a 10-foot pole (scams aside):
PDLI
THRX (hate this one, not a bad company, but $1.4 billion for yet another antibiotic?)
Anybody else? I mean, aside from HEPH.
Thomas,
Would you please list the 6/7 phase IIIs and 7 phase IIs? I'm not getting the same number.
John
OT: Large-cap outperformance
I rather like this analysis. I’m tired of hearing how large-cap growth stocks are going to outperform. My recollection is that outperformance was predicted last year and the year before.
An article from the Dec. 21 issue of The Wall Street Journal revealed that 80% of the respondents from a survey of 112 money managers by Russell Investment Group like the prospects for large-cap growth stocks. This was "the most bullish reading for any asset class in the two-year history of the survey."
A similar theme is evident in BusinessWeek's "Where to Invest 2006" year-end issue: Large-cap will outperform small-cap, and growth will outperform value.
If this sounds to you like the same "quality trade" that has been recommended by the usual suspects on Wall Street for the past three years -- with dismal results -- you are correct. And I believe the prognosis for this extremely crowded trade is equally woeful for 2006.
Wait a minute, Schaeffer, you might say. Don't be so smug. Aren't you the one who forecast a major market decline for 2005?
Yes, I did, and my biggest mistake was in translating my negative outlook for the non-energy mega-cap blue chips (which did perform quite poorly) into a broadly negative market view. In fact, there were a number of areas of the market I had identified as being quite promising for 2005, such as the small- and mid-cap sectors, that I simply did not emphasize enough. Mea culpa.
But back to the subject at hand. Just how poorly did the mega-caps perform this year? As of Dec. 22, the year-to-date changes for the "top 10" in market capitalization in the S&P 500 are as follows:
• AIG (AIG:NYSE - commentary - research - Cramer's Take) (up 3.4%)
• Bank of America (BAC:NYSE - commentary - research - Cramer's Take) (down 0.1%)
• Citigroup (C:NYSE - commentary - research - Cramer's Take) (up 2.2%)
• Exxon Mobil (XOM:NYSE - commentary - research - Cramer's Take) (up 11.4%)
• GE (GE:NYSE - commentary - research - Cramer's Take) (down 3%)
• IBM (IBM:NYSE - commentary - research - Cramer's Take) (down 15.6%)
• Johnson & Johnson (JNJ:NYSE - commentary - research - Cramer's Take) (down 3.3%)
• Microsoft (MSFT:Nasdaq - commentary - research - Cramer's Take) (down 0.5%)
• Pfizer (PFE:NYSE - commentary - research - Cramer's Take) (down10.5%)
• Wal-Mart (WMT:NYSE - commentary - research - Cramer's Take)(down 8%).
The tally is three winners (two excluding energy behemoth Exxon Mobil) and seven losers.
One of the most powerful bearish contrarian situations occurs when the crowd continues to be wildly bullish on an asset class even in the face of dismal performance. This situation has presented itself time and again in recent years with regard to the mega-cap blue chips, and it is reason enough to be extremely skeptical once again about the prognosis for these stocks. But rather than succumbing to concluding on a negative note, especially as we move into the new year, I'd like to leave you with a bullish opportunity that presents itself as a result of this hugely skewed crowd opinion.
Everyone "knows" that large-cap will outperform small-cap in 2006, do they not? And, likewise, doesn't everyone also "know" that growth stocks will outperform value stocks? So let's consider the bullish case for the ultimate contrarian product of these crowd-based conclusions -- small-cap value stocks.
The accompanying two weekly charts focus on the iShares Russell 2000 Value Index Fund (IWN), an exchange-traded fund. Note the solid, multiyear uptrend for IWN as well as its performance relative to the S&P, supported in each case by a rising 80-week moving average. As a technician, I'm particularly interested in the relative-strength chart, as I believe IWN is approaching its 80-unit support level in the wake of all the gloom and doom being expressed about small-cap value; I'd ultimately expect a major bounce off this support similar to that which occurred earlier in 2005.
But for a sector to be a "buy candidate," bullish technicals need to be accompanied by negative and skeptical sentiment. Small-cap value qualifies in spades on the sentiment front, as I've just discussed. There is also healthy short interest in IWN, which indicates that, in addition to Wall Street, the fast-money community is bearish on small-cap value.
My advice to you for 2006 is to run (not walk) from the "safety" of the mega-caps and the "throw caution to the wind" investment commitment recommended by Wall Street. These stocks offer very little upside potential in exchange for all the downside risk of a bear market. And look for opportunity sectors, such as small-cap value, in which to invest a prudent portion of your assets.
New ideas...
>praveen and rfj appear to find new stocks just about every week to purchase, whereas I've made less than a half dozen purchases all year.<
There are a few reasons for this:
1) I try to buy stocks that I believe are undervalued. Once I view them as fairly valued, I don't add further to my position. Because the past two years have been extraordinary for biotechs, I frequently fail to establish a full position at a price I feel is fair. XNPT being the most recent example.
2) I'm always interested in new ideas because the information I uncover is valuable to me professionally even if I do not invest. For example, I've followed PANC for a while. I'd never buy it, but it is interesting becuase I do a lot of work on HIV.
3) I have worked in many therapeutic areas, so I am fairly comfortable with a broad range of topics; plus if I don't understand something I can always ask a colleague or on here.
4) I do trade more often than you, but never more than once or twice a month. That said, there is value in buying and holding no matter what: my tracking portfolio, which contains all the stocks that I have ever been seriously interested in (about 25), has tripled over the past two years despite containing losers like NABI, RIGL, and ISTA. I wish it was my real portfolio.
The more ideas I have to pick from, the happier I am. I have a lot of respect for many of the posters here, and as an idea-generating mechanism this board has been great.
Given Dr Praveen's results, I think he should start a newsletter. I'll subscribe.
Cytos--Dr Praveen,
Sorry you had a problem with E-Trade. My broker told me that it is possible to buy Speedel online by placing a limit order.
As an experiment, I just placed a limit order for a small position in Cytos (CSBTF). Thanks again for leading me to that company; it is a little too early-stage for me but their products have a lot of promise and the breadth of their portfolio is impressive. Certainly worth a token investment at this time.
I'll let you know what happens with my order.
John
Repatriation
Anyone know the rules for use of repatriated profits? My understanding is that the tax break is not dependent on spending the money before end of year; instead, it goes into the company coffers to be spent when and where they see fit.
J
Speedel
Can anyone tell me what the terms are for the Novartis-Speedel SPP100 deal?
Thanks!
Dr Praveen--
I think both Cytos and GenMab are interesting, thanks for the heads up. The former becuase of the science, the latter becuase of the association with Amgen. Looking into both.
Although early, I was particularly intrigued by the hypertension vaccine. I have my doubts, but it is interesting.
Pretty soon my entire portfolio is going to be ex-US. Still looking at Speedel; I own CRME and YMI and may own FMTI in mid- to late-2006.
John
Why Jim Cramer should never be taken seriously (from Mad Money Friday Recap):
"Neurocrine Biosciences (NBIX:NYSE - commentary - research - Cramer's Take): "Unbelievable earnings breakout. ... This is a company that is closer on the Alzheimer's front." BuyBuyBuy."
I've owned NBIX all this time, and never knew they had an AD research program. Thanks Jim!
Watch NBIX on Tuesday.
Another BCRX bonanza....
Up 15% today. Too bad I didn't repurchase.
NEW YORK (AP) -- Shares of BioCryst Pharmaceuticals Inc. jumped Thursday after the Food and Drug Administration gave the drug developer the green light to begin testing of a new potential bird flu treatment.
ADVERTISEMENT
BioCryst shares were up $1.66, or 11 percent, to $16.87 on the in midday trading on the Nasdaq at more than double their average volume, and earlier changed hands as high as $17.93. The stock has risen from a 52-week low of $3.68 in April to hit a year high of $18.42 in October.
The company said the FDA gave it verbal approval to begin early stage clinical trials of intravenous peramivir, BioCryst's injectable flu medication designed for a wide variety of flu strains, including the H5N1 bird flu. Testing is expected to begin early in the first quarter.
The news comes a day after the New England Journal of Medicine published a study showing that two out of eight bird flu patients in Vietnam had developed a resistance to Roche Holding Ltd.'s popular flu drug Tamiflu and died. One of the patients who died had been given Tamiflu early enough to receive a full course of the treatment. The study said additional antivirus drugs needed to be developed to fight stains like bird flu.
In a research note, investment firm Wedbush Morgan reiterated its "Buy" rating and $24 price target for BioCryst.
"We note that the viral mutations that confer Tamiflu resistance to H5N1 would not appear to affect the potency of other antiviral drugs including peramivir," Wedbush analyst Vinny Jindal told investors.
BioCryst also announced Thursday it started an early-to-mid stage clinical trial of its lead drug Fodosine for the treatment of cancers of the immune system.
YMI: Press Releases
My question yesterday regarding the requirement for press releases was related to YMI's many upcoming trials, including the taxotere/tesmilifene trial, the Aerolef phase IIb, lung cancer, stomach cancer, and the US and pivotal European phase IIIs for nimotizumab.
Just got a response from IR and they will be issuing press releases, but "only when the first patient is enrolled and not before."
So no worries about whether we are going to see PRs for each of these trials. Looks like we have a lot to look forward to in 1H06.
John
Urche--
There is a very good guide to the the Medicare prescription drug plan in this month's issue of Money magazine.
John
>Often large pharmas do not issue a press release about the initiation of a clinical trial, particularly a Phase I or II trial, as they do not want to tip their hand to their competition<
I think the reason why large pharmas do not issue press releases about phase I or II trials (and many phase III trials) is that it would result in an enormous volume of press releases. As an example, Pharmacia had well over 300 ongoing oncology clinical trials when it was taken over by Pfizer. Moreover, unless the trial is of critical importance, the results will not substantially influence the share price.
My opinion: For a small biotech, initiation of a phase II or phase III trial should be considered a material event. I want to know the patient population, end points, and time frame of the trial because the results have a huge impact on the potential value of the company.
Aside from that, press releases serve the valuable function of gaining attention. I do not support the press-release-a-day approach of some small biotechs, but any substantive news should be released to their investors.
Question regarding press releases
Is initiation of a clinial trial a material event? If a trial is initiated, is a press release required?
The one on the left is clopidogrel, the one on the right is atorvastatin.
Clopidogrel would obviously be more useful in the short term to prevent thrombotic events. However, atorvastatin may have some benefit through reducing inflammation at the site of iatrogenic injury.
John
IMMU
Anyone have any comments/criticisms of IMMU? Aside from the shaky balance sheet, which I think will be rectified shortly when their lupus drug is partnered.
Still looking for ideas. Bladerunner--I think SPPI is interesting but I'm afraid of management.
John
Ideas
I finally convinced a bunch of clients to pay me, so anyone want to give me some new biotech ideas? Looking for a deep pipeline, multiple drugs in phase 3, partnerships, etc.
I'll do a RMF for one or two of them in return. I may need to take my medication, but recently whenever I think about buying a stock it starts to go up and I miss the boat.
John
XNPT
Adopts a "shareholder rights" plan.
http://biz.yahoo.com/prnews/051216/sff015.html?.v=35
Will add to the RMF later.
J
Full disclosure
Just thought I'd share too. My portfolio currently consists of:
NBIX
SNUS
CRME
TELK calls (tiny position)
YMI
XNPT
HEPH calls (tiny position)
In order of best to worst performer.
I sold DSCO because management lied. I accidentally sold CONR. No kidding, my first-ever order entry mistake. As it turns out, my mistake saved me a little bit of money. Plan to repurchase soon.
Looking at THLD.
Pans: PANC and any biotech without products in entering or in phase 3
Keep in mind HEPH is an exception. I considered it a lottery ticket. Anyway, the amount I invest in each option position is equivalent to one day's swing in the value of my portfolio. That way, if I lose it all it's no worse than an average bad day.
Vaccinating against HPV
Although I am not working on the HPV vaccines, I do know that the companies involved are devoting tremendous resources to educating physicians and parents about the need for these vaccines. The materials they are producing mainly focus on how to explain to a teenage girl why she needs an HPV vaccine.
J
OTC Niacin
Another difference is, of course, the prescription niacin is much higher dose than anything you can get OTC. At least if you follow the dosing recommendations.
>>I’ve said all along that IMCL’s “combo use” patent is of little value and may even be worthless because it doesn’t surpass the threshold for being non-obvious. AMGN evidently agrees.<<
And I agree too. AMGN has deep pockets and will devote substantial resources to breaking that patent. Provided near-equivalent efficacy, nimotuzumab is an inherently superior product, so the prospects are getting better and better for YMI. I'll take $1.1B.
I'm sure Silverback will spoil the party....
On a related note, I see the booyah brigade has arrived on the YMI YMB.
OT: Regarding the profitability of medical writing...
I guess the relative profitability of professional investing depends on the amount of capital you have to invest.
On average, my freelance colleagues make around $100 to $150 an hour, and have more work than they can handle. Keep in mind that my colleagues live in New York City, the land of $4000/month rents, rates may be different elsewhere.
I know at least one freelancer who makes well in excess of $500,000 with few expenses aside from an assistant.
(This is in response to Dew's message, not Biowatch's--sorry!)
ABGX and YMI
Now this ought to light a fire under YMI.
Admittedly, some of that purchase price is because of AMG162; nevertheless panitumumab is probably the primary value driver given that it is closest to approval.
Now I will shut up and work.
J
ABGX
I don't own it, unfortunately, but satisfying, to say the least!
J
NEW YORK, Nov 25 (Reuters) - Below are the five Nasdaq issues that experienced the largest increases and decreases in their short positions in November, according to information released by the market on Tuesday. The five companies with the largest overall short positions are also listed.
Company November October Pct change ------------------------------------------------------------------------------
Five biggest increases: Microsoft Corp. (MSFT,Trade) 113,855,082 85,291,148 33.49 Cadence Design Systems Inc. (CDN,Trade) 7,944,885 0 100 Yahoo Inc. (YHOO,Trade) 86,717,343 79,159,966 9.55 eBay Inc. (EBAY,Trade) 45,703,671 38,216,470 19.59 Abgenix, Inc. (ABGX,Trade) 14,095,064 8,525,210 65.33